Back to Search
Start Over
Incyte pulls FDA filing for cancer drug approval over confirmatory study, following Gilead out of the exit.
- Source :
- FierceBiotech; 1/26/2022, pN.PAG-N.PAG, 1p
- Publication Year :
- 2022
-
Abstract
- The follicular lymphoma market is thinning out fast. Days after Gilead pulled an accelerated approval for Zydelig in the indication, Incyte has withdrawn a submission for approval of its rival PI3K inhibitor in response to talks with the FDA about confirmatory studies. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- Database :
- Complementary Index
- Journal :
- FierceBiotech
- Publication Type :
- Periodical
- Accession number :
- 154929285